Photo via The Straits Times

US FDA rejects closely watched lung cancer drug from China

Read the original at The Straits Times ↗
Cite

The Straits Times. (2026, November 16). US FDA rejects closely watched lung cancer drug from China. The Straits Times. https://www.straitstimes.com/world/united-states/us-fda-rejects-closely-watched-lung-cancer-drug-from-china

Dated from the outlet's own feed. Check the original for its byline.

Share
The Straits Times · collected 2026-11-16 · by The Straits Times

Quick Summary

The US Food and Drug Administration (FDA) rejected a novel lung cancer drug developed in China by Akeso Biopharma. Summit Therapeutics, which had acquired the US rights to the drug, announced the FDA’s decision on November 15. This rejection marks a significant setback for China’s growing presence in pharmaceutical innovation.
Written by AI on 2026-11-16, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

The US Food and Drug Administration (FDA) rejected a groundbreaking lung cancer drug invented in China, dealing a significant blow to China’s ambitions in the global pharmaceutical industry. The drug, which was developed by Akeso Biopharma in China and licensed to Summit Therapeutics in Florida, was seen as a symbol of China’s growing prowess in drug development. Summit Therapeutics announced the FDA’s decision on November 15, 2026, marking a setback for the company’s efforts to bring the drug to the US market. The rejection highlights the rigorous standards set by the FDA and the challenges faced by international pharmaceutical companies in gaining approval in the United States.

Written for “FDA Rejects Chinese Lung Cancer Drug” on 2026-11-16, grounded in this article and the 0 other(s) covering the same event.
Why this leaning score
The article's own words the score was based on. Each is quoted verbatim and was checked against the article text before being stored, so you can find it in the original.
Reading Leans left (beta estimate) Confidence medium
Leaning: leans left for article 156181 (medium confidence, 1 verified quote) · logged 2026-11-16

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.

Story

FDA Rejects Chinese Lung Cancer Drug
Health · 1 article(s) covering the same event.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
4
sentences that state something as happening or true
Uncertain
0%
0 of 4 hedged ("reportedly", "may", "according to")
Leaning
Leans left
of the writing, not the subject · beta estimate
Publisher signals
64/100
The Straits Times's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-16 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

The Straits Times · 5203 article(s) · 7 correction(s) detected
Running correction rate · 7 correction(s)

Who wrote this

The Straits Times
3589 article(s) here · 0 carrying a prediction
Major arms producers the United States and Russia look set to oppose a push at a global meeting in Geneva this week to launch negotiations on legally binding rules for autonomous weapons, in what diplomats and rights groups expect to be difficult talks.
Beijing confirmed on Nov 16 that President Xi Jinping and his US and Russian counterparts Donald Trump and Vladimir Putin will hold their first trilateral summit on Nov 19 in the southern Chinese city of Shenzhen.
Blue Origin's New Glenn rocket with the BE-4 engine had a launchpad explosion in May, and its investigation determined the engine was the cause.
Amnesty found that recruiters were telling workers before they left their home countries that they would be employed directly by Amazon on long contracts.
Major arms producers the United States and Russia look set to oppose a push at a global meeting in Geneva this week to launch negotiations on legally binding rules for autonomous weapons, in what diplomats and rights groups expect to be difficult talks.
Blue Origin's New Glenn rocket with the BE-4 engine had a launchpad explosion in May, and its investigation determined the engine was the cause.
Rising to prominence in the 1970s, the former cartel kingpin was an architect of Mexico's modern drug-trafficking trade, igniting a series of turf wars that have led to hundreds of thousands of deaths and disappearances in ensuing decades. Born in 1946 in Culiacan, Sinaloa, a northwestern state that would later become synonymous with narco-trafficking, he worked as a police officer and bodyguard for a local governor then became a powerful criminal capo known as the "boss of bosses." Felix Gallardo and others set up the cartel in Guadalajara, the Jalisco state capital and a fast-growing economic powerhouse, becoming the first to move cocaine to the US on a massive scale and to forge an alliance with Colombian drug barons, including Pablo Escobar's Medellin cartel.
Leo draws millions in Peru Church leaders hoped more Peruvians would have an opportunity on Nov 15 to attend events with Leo.
Burnham is aiming for an agreement at Friday's summit on areas such as food and youth mobility, which could help lower costs for consumers in the short term and ease some of the frictions caused by Britain's departure from the bloc in 2020.
Britain's Prince Harry met soldiers wounded in action during a two-day visit to Ukraine, expressing confidence that it could win the war against Russia and pledging to bring his Invictus Games to the country once there was peace.
2026-11-15 · assertive framing · Britain's Prince Harry visits war-wounded in Ukraine
Also by The Straits Times
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 3589 articles by The Straits Times →

Topics

China FDA Florida Summit Therapeutics The US Food and Drug Administration

Subjects

China GPE · 4× FDA ORG · 2× Akeso Biopharma ORG · 1× Chinese NORP · 1× Florida GPE · 1× Rebecca Robbins PERSON · 1× Summit ORG · 1× Summit Therapeutics ORG · 1× The US Food and Drug Administration ORG · 1×

Narrative

The US Food and Drug Administration (FDA) rejected a first-of-its-kind cancer drug that was invented in China, a setback for a medicine that had become a symbol of China’s ascendance as a powerhouse in drug development.
framing: assertive · carried by 1 article(s) · first seen 2026-11-16
2026-11-16 · The Straits Times
US FDA rejects closely watched lung cancer drug from China · assertive framing

Claims (4 extracted, 0 hedged)

US FDA rejects closely watched lung cancer drug from China Rebecca Robbins AI generated asserted
AI → reject → China
The US Food and Drug Administration (FDA) rejected a first-of-its-kind cancer drug that was invented in China, a setback for a medicine that had become a symbol of China’s ascendance as a powerhouse in drug development. asserted
that → reject → development
Summit Therapeutics, the Florida company that has been seeking to bring the drug to the US market, disclosed the agency’s decision in a news release on Nov 15. asserted
that → seek → Nov
Summit bought the US rights to the drug from Akeso Biopharma, a Chinese drugmaker that invented the drug in its laboratories and sells it in China. asserted
that → buy → China
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support